P-ISSN 2587-2400 | E-ISSN 2587-196X
EJMO. 2017; 1(1): 1-7 | DOI: 10.14744/ejmo.2017.22931

Frequency of Ras Mutations (Kras, Nras, Hras) in Human Solid Cancer

Hilmi Kodaz1, Osman Kostek2, Muhammet Bekir Hacioglu2, Bulent Erdogan2, Cagnur Elpen Kodaz3, Ilhan Hacibekiroglu4, Esma Turkmen2, Sernaz Uzunoglu2, Irfan Cicin2
1Department of Medical Oncology, Acibadem Eskisehir Hospital, Eskisehir, Turkey, 2Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey, 3Department of Health, Acibadem Eskisehir Hospital, Eskisehir, Turkey, 4Department of Medical Oncology, Sakarya University Faculty of Medicine, Sakarya, Turkey

RAS oncogene affects numerous cellular functions including growth, proliferation, apoptosis, migration, division and differentiation of the cells. It has 3 known isoforms as Harvey- RAS (HRAS), Kirsten - RAS (KRAS) and Neuroblastoma- RAS (NRAS). RAS has an intrinsic GTPase activity. It encodes proteins binding the guanine nucleotides. KRAS and HRAS were discovered in studies carried out on viruses leading to cancer. Retroviral oncogenes related to murine sarcoma virus genes (Kristen Rat Sarcoma Virus and Murine Sarcoma Virus) were discovered in 1982. These two oncogenes are similar to human KRAS. Approximately 30% of all human cancers have ras genes. Mutations in KRAS account for about 85% for all RAS mutations in human tumors, NRAS is about 11–15%, and HRAS is about 1%.


Frequency of Ras Mutations (Kras, Nras, Hras) in Human Solid Cancer. EJMO. 2017; 1(1): 1-7

Corresponding Author: Hilmi Kodaz

Full Text PDF